ALENTIS’ UNIQUE CLDN1 MONOCLONAL ANTIBODIES
CAN REVERT THE EXTRACELLULAR MATRIX TO ITS
HEALTHY STATE IN CANCERS AND ORGAN TISSUES
Alentis is developing a portfolio of first-in-class anti-CLDN1 monoclonal antibodies (mAbs) that bind to CLDN1 exposed outside of the tight junction to treat cancers and fibrotic diseases
CLDN1 mAb has been designed with an effector function directly targeting cancer while silencing CLDN1-mediated carcinogenic signaling and opening up the stiff extracellular matrix (ECM) in tumors with immune evasive properties. IND-enabling studies are currently ongoing.
CLDN1 mAb has been designed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs and is currently under development for kidney, lung, and liver fibrosis. ALE.F02’s translational data predict robust efficacy and safety across multiple organ fibrosis indications. Phase 1 in healthy volunteers is ongoing with data expected in Q1 2023.
Next Generation: Alentis CLDN1 Technology (ACT) Platform
The Next Generation CLDN1 Platform is under development for an enhanced mechanism of action in several indications to expand approaches for ECM restoration and to develop and potentiate the efficacy of cancer treatments. Among others Alentis is exploring antibody drug conjugates (ADCs) and potential other payloads and approaches.